NBC News gained rare, exclusive access to Yichang Humanwell Pharmaceutical’s high-security headquarters in Yichang, China. Behind a glass wall, a worker in full protective gear oversaw hundreds of tiny vials racing along an automated line where robotic arms sterilized, filled, inspected, stamped and boxed fentanyl products destined for hospital use. Humanwell’s president, Du Wentao, said the company produces around 100 million doses of fentanyl variants a year, is one of only five firms licensed to make the drug for medical use in China, and has “never had a single incident of a drug going missing.” The facility is surrounded by fences with concertina wire and electronic sensors, and all visitors, including executives, wear caps, shoe covers and lab coats. Alarms ping every 10 minutes to prompt hand disinfection while vials are visually inspected by flashes of light and sent to the warehouse.
Humanwell told NBC it does not export medications to the United States, Mexico or Canada. Du argued China’s fentanyl controls are among the strictest in the world and said no dose from the company could have reached the United States. NBC also visited China’s National Narcotics Intelligence Center in Beijing, where officials said they are again exchanging information with U.S. counterparts on changing smuggling tactics. Lab director Hua Zhendong said precursor chemicals are a main concern and that newly identified substances from the United States are added to China’s monitoring list.
The reporting came as President Donald Trump met President Xi Jinping in South Korea. Trump said he would reduce his fentanyl tariff on China from 20 percent to 10 percent after Xi agreed to intensify efforts to stem the illicit international flow of precursors. U.S. officials maintain Beijing has not done enough and cited a State Department report that accused authorities of subsidizing exports of synthetic drug precursors. Chinese officials rejected that, insisting China has strict rules and has curbed illegal production since a 2019 ban on non-medical fentanyl.
Yichang Humanwell manufactures medically approved fentanyl products, including injections and other variants used in hospitals. Inside, most of the process is automated to limit human contact. Vials are washed, sterilized, filled via long rubber tubing, sealed and boxed. Staff in protective suits supervise the line, disinfecting at set intervals. The entire operation is designed to prevent contamination and diversion, with layers of access controls and visible security infrastructure.
The Background: From China’s Labs to U.S. Streets
American officials say China remains a central source of precursor chemicals that Mexican labs turn into illicit fentanyl smuggled into the United States. While U.S. overdose deaths appear to be declining, synthetic opioids, chiefly fentanyl, have killed hundreds of thousands of Americans in recent years. China counters that it has cracked down, points to the 2019 class-wide scheduling of fentanyl, and blames unrelenting U.S. demand. Experts caution that enforcement is complicated because there is no fixed list of precursors and many chemicals are dual use, making interdiction and regulation difficult.
China has authorized a limited group of manufacturers to produce narcotic APIs and medicines under strict domestic controls. As of late 2023, five companies held licenses for fentanyl production. Yichang Humanwell is the market leader, with dominant shares in remifentanil, sufentanil and alfentanil, and operates large R&D and production centers across Asia. By law, licensed manufacturers sell only to three national wholesalers that supply hospitals. Company data indicate a primarily domestic focus and no FDA approvals for U.S. clinical sales, limiting legal exports to the American market.
Inside the Enforcement Gap
Despite formal controls, U.S. officials and investigators describe persistent flows of precursors and related chemicals from smaller private chemical firms. Veteran analysts say shutting down one route often leads sellers to pivot to new formulas and labels. The resumption of U.S.–China counternarcotics exchanges may improve targeting, but experts warn that the problem will not disappear quickly.
- Hubei Aoks Bio-Tech (Wuhan)
Indicted in U.S. federal court for selling fentanyl precursors and xylazine. Exported chemicals to at least 100 countries and tailored sales for markets like Mexico, shipping 25-kilogram drums said to yield up to 10 million pills. Disguised imports as furniture parts, vases and makeup. Following the indictment, Chinese authorities dissolved the company and arrested four employees. - Yafeng Biological Technology, linked to Shijiazhuang Prison (Hebei)
A congressional investigation and records reviewed by ProPublica found a prison-owned firm operated websites selling fentanyl products and precursors, boasting that shipments would clear customs. The company and affiliated sites marketed drugs illegal in China and the U.S., illustrating alleged state-connected involvement in the pipeline. - Hubei Amarvel Biotech
Advertised “100 percent stealth shipping” with drugs disguised as nuts, dog food and motor oil. Two executives were lured to Fiji and arrested; a New York jury later convicted them on importation and money laundering charges. - Gaosheng Biotechnology (Shanghai)
Described by investigators as wholly state-owned. Operated nearly 100 websites selling precursors and illicit narcotics to overseas buyers and received praise from provincial development officials for economic contributions. - Zhejiang Netsun
A firm with government ties alleged to have executed hundreds of sales of illegal narcotics and provided billing or technical services to more than 100 similar companies, including Yafeng. - Shanghai Ruizheng Chemical Technology
Received local monetary awards and export credits while openly advertising fentanyl products on major platforms. Officials invited company representatives to policy roundtables despite the alleged sales. - Zheng Organization (Shanghai hub with U.S. reach)
Accused of trafficking across dozens of U.S. states. U.S. prosecutors brought charges, and Treasury designated the son as a drug kingpin. Chinese authorities declined to prosecute, and the defendants remain in China. - Chuen Fat Yip Network
Firms linked to Yip allegedly distributed hundreds of millions of dollars in synthetic drugs. Even after targeted bans, associated actors resurfaced under new company names, illustrating the cat-and-mouse dynamic.
Why Precursors Are So Hard to Stop
Experts stress that the list of fentanyl precursors is fluid and the chemicals often have legitimate industrial uses. Sellers adapt rapidly, altering formulas and product labels to evade new rules. Chinese officials say they add newly identified substances to monitoring lists and emphasize domestic bans outside medical use. U.S. officials remain skeptical that such steps match the scale of the problem, citing reports of subsidies and permissive environments for exporters.
NBC’s inside look at Yichang Humanwell showcases China’s tightly controlled medical fentanyl production, with automation, traceability and strict access protocols. Yet the broader crisis pivots on smaller chemical firms and agile supply chains that feed illicit markets. Even as Washington and Beijing resume cooperation, investigators say enforcement will hinge on tracking ever-shifting precursors, closing regulatory gaps that allow dual-use chemicals to slip through, and sustaining pressure on exporters who adapt faster than the rules can change.